Table 3.
Phase III trials of chemotherapy and surgery for resectable esophageal and gastric carcinomas including gastroesophageal junction cancers
| Trial | N | Site | Histology | GEJ | CT regimen | Curative resection
|
OS
|
|||
|---|---|---|---|---|---|---|---|---|---|---|
| S | CS | S | CS | Yrs | ||||||
| Intergroup 011322 | 440 | E | SCC 46%
ADC 54% |
NR | CF: preop × 3, postop × 2 | 59% | 62% | 26% | 23% | 3 |
| MRC23,24 | 802 | E | SCC 31%
ADC 66% |
10%* | CF: preop × 2 | 54% | 17%
60%† |
23%† | 5 | |
| FFCD 970325 | 224 | E/G | ADC 100% | 64%* | CF: preop × 2–3 | NR | NR | 24% | 38%† | 5 |
| MAGIC28 | 503 | G | ADC100% | 12% | ECF: preop × 3, postop × 3 | 66% | 69% | 23% | 36%† | 5 |
*Designated as cardia in study.
† Statistically significant.
Abbreviations: NR = not reported; GEJ = gastroesophageal junction; CT = chemotherapy; OS = overall survival; S = surgery alone; CS = chemotherapy plus surgery; E = esophageal; G = gastric; SCC = squamous cell carcinoma; ADC = adenocarcinoma; preop = preoperative; postop = postoperative; CF = cisplatin + 5-FU; ECF = epirubicin + cisplatin + 5-FU; MRC = Medical Research Council; FFCD = Fédération Francophone de la Cancérologie Digestive; MAGIC = Medical Research Council Adjuvant Gastric Infusional Chemotherapy.